

## REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

**Copenhagen, Denmark; June 22, 2011 – Pursuant to Section 28a of the Danish Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on transactions by managerial employees and their related parties involving Genmab shares and related instruments, as follows:**

Name: Michael B. Widmer  
Reason: Chairman of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 20,000  
Value: DKK 448,800

Name: Anders Gersel Pedersen  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

Name: Karsten Havkrog Pedersen  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

Name: Burton G. Malkiel  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

## REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

Name: Hans Henrik Munch-Jensen  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

Name: Nedjad Losic  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

Name: Tom Vink  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

Name: Daniel Bruno  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 10,000  
Value: DKK 224,400

Name: Toon Wilderbeek  
Reason: Member of the Board of Directors  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S

## REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

Number: 10,000  
Value: DKK 224,400

Name: Jan G. J. van de Winkel  
Reason: President & Chief Executive Officer  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 100,000  
Value: DKK 2,244,000

Name: David A. Eatwell  
Reason: Executive Vice President & Chief Financial Officer  
Issuer: Genmab A/S  
ID code/ ISIN: DK0010272202  
Description: Warrants  
Transaction: Grant  
Trading date: June 22, 2011  
Market: NASDAQ OMX Copenhagen A/S  
Number: 80,000  
Value: DKK 1,795,200

The exercise price for each warrant is DKK 40.41. Each warrant entitles the owner to subscribe one share of nominally DKK 1. On the basis of an exercise price of DKK 40.41 and by application of the Black-Scholes formula, the average value of each warrant can be calculated as DKK 22.44 based on an interest rate of 2.5233% and the historical volatility of Genmab A/S shares calculated at 62.28%.

### About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, Arzerra® (ofatumumab), was approved to treat refractory chronic lymphocytic leukemia after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit [www.genmab.com](http://www.genmab.com).

### Contact:

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication  
T: +45 33 44 77 20; M: +45 25 12 62 60; E: [r.gravesen@genmab.com](mailto:r.gravesen@genmab.com)

*This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on [www.genmab.com](http://www.genmab.com). Genmab does not undertake any obligation to*



## REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

*update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.*

Genmab<sup>®</sup>, the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; HuMax-CD20<sup>®</sup>; HuMax-EGFr<sup>™</sup>; HuMax-IL8<sup>™</sup>; HuMax-TAC<sup>™</sup>; HuMax-CD38<sup>™</sup>; HuMax-TF<sup>™</sup>; HuMax-Her2<sup>™</sup>; HuMax-cMet<sup>™</sup>, HuMax-CD74<sup>™</sup>, DuoBody<sup>™</sup> and UniBody<sup>®</sup> are all trademarks of Genmab A/S. Arzerra<sup>®</sup> is a trademark of GlaxoSmithKline.